RT Journal Article
T1 Challenging boundaries: is cross-protection evaluation necessary for African swine fever vaccine development? A case of oral vaccination in wild boar
A1 Cadenas Fernández, Estefanía
A1 Barroso Arévalo, Sandra
A1 Kosowska, Aleksandra
A1 Díaz Frutos, Marta
A1 Gallardo, Carmina
A1 Rodríguez Bertos, Antonio Manuel
A1 Bosch López, Jaime Alfonso
A1 Sánchez-Vizcaíno Rodríguez, José Manuel
A1 Barasona García-Arévalo, José Ángel
AB African swine fever (ASF) poses a significant threat to domestic pigs and wild boar (Sus scrofa) populations, with the current epidemiological situation more critical than ever. The disease has spread across five continents, causing devastating losses in the swine industry. Although extensive research efforts are ongoing to develop an effective and safe vaccine, this goal remains difficult to achieve. Among the potential vaccine candidates, live attenuated viruses (LAVs) have emerged as the most promising option due to their ability to provide strong protection against experimental challenges. However, ASF virus (ASFV) is highly diverse, with genetic and phenotypic variations across different isolates, which differ in virulence. This study highlights the limitations of a natural LAV strain (Lv17/WB/Rie1), which showed partial efficacy against a highly virulent and partially heterologous isolate (Arm07; genotype II). However, the LAV's effectiveness was incomplete when tested against a more phylogenetically distant virus (Ken06.Bus; genotype IX). These findings raise concerns about the feasibility of developing a universal vaccine for ASFV in the near future, emphasizing the urgent need to assess the protective scope of LAV candidates across different ASFV isolates to better define their limitations.
PB Frontiers Research Foundation
YR 2024
FD 2024
LK https://hdl.handle.net/20.500.14352/109443
UL https://hdl.handle.net/20.500.14352/109443
LA eng
NO Cadenas-Fernández E, Barroso-Arévalo S, Kosowska A, Díaz-Frutos M, Gallardo C, Rodríguez-Bertos A, Bosch J, Sánchez-Vizcaíno JM and Barasona JA (2024) Challenging boundaries: is cross-protection evaluation necessary for African swine fever vaccine development? A case of oral vaccination in wild boar. Front. Immunol. 15:1388812. doi: 10.3389/fimmu.2024.1388812
NO Contrato Ramón y Cajal para J.B
NO European Commission
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 21 abr 2025